No Data
Accelerating recovery? In March, domestic Innovative Drugs investment and financing increased by about 50% year-on-year, and the Hong Kong Stock pharmaceutical Sector collectively surged.
① In March, domestic investment and financing for Innovative Drugs increased by approximately fifty percent year-on-year, how significant is the Bullish impact? ② The Hong Kong stock market's pharmaceutical Sector rose collectively, which stocks are attracting market attention?
Private Companies Account for 33% of Shanghai Pharmaceuticals Holding Co., Ltd's (SHSE:601607) Ownership, While Individual Investors Account for 33%
SH PHARMA (601607.SH): The hydrochloride valaciclovir tablets have received approval from the FDA in the USA.
Gelonghui, April 22 - SH PHARMA (601607.SH) announced that its subsidiary Shanghai Shanyao Zhongxi Pharmaceutical Co., Ltd. received notification from the USA Food and Drug Administration (abbreviated as "USA FDA") that its abbreviated new drug application ("ANDA", i.e. USA generic drug application) for Valganciclovir Hydrochloride Tablets has been approved ("Approval"). Valganciclovir Hydrochloride Tablets are primarily used for the treatment of cytomegalovirus (CMV) retinitis in adults with acquired immunodeficiency syndrome (AIDS); they prevent CMV infection in patients at risk undergoing solid organ transplantation.
Hong Kong stocks in the pharmaceutical sector soared! Kai Medical surged more than 22%. Institutions claim that tariffs have "no impact" on the wave of Innovative Drugs going abroad.
① How do government policy support and the overseas expansion of Innovative Drugs become a new growth engine for Hong Kong stock pharmaceutical companies? ② Why does Zhongtai International believe that tariffs have limited impact on Innovative Drug companies?
Earnings Preview: SH PHARMA to Report Financial Results on April 28
Has the SSE Health Care theme Index risen again? This year, the public fund performance has shuffled, with the highest return of the health care theme Fund exceeding 44%, and Inflow of capital has accelerated.
As of April 16, two SSE Health Care theme Index Funds have entered the top 10 performances of actively managed equity funds this year; Since April, multiple Hwabao WP CSI Medical Service ETFs have seen significant net subscriptions, with the total amount of fund shares for these medical ETFs reaching a new high; Fund managers believe that the pharmaceutical sector is not just undervalued in parts, but is comprehensively undervalued, and the nature of Innovative Drugs has changed.
Return Trends At Shanghai Pharmaceuticals Holding (SHSE:601607) Aren't Appealing
